Hikma Pharmaceuticals Share Discussion Threads

[r ball] 21/9/2015 19:48

Encouraging.

[r ball] 08/9/2015 08:39

Resilient given that takeover "rumour" has diminished.

[coppertrader] 05/9/2015 23:07

West-Ward Pharmaceuticals Corp. is a wholly owned, U.S. subsidiary of Hikma Pharmaceuticals PLC, based in Amman, Jordan, and headquartered in London, England. Hikma (HIK.L) develops, manufactures, and markets a broad range of pharmaceutical products spanning 45 countries across the U.S., Europe, Middle East, and North Africa. The business is conducted through 3 segments: branded, injectables, and generics with 27 manufacturing facilities worldwide. Hikma's revenues for the year 2014 were nearly $1.5 billion globally.West-Ward is the U.S. operations arm of Hikma responsible for marketing, planning, and distributing products in both the injectable and non-injectable business units. West-Ward is supported by 6 FDA-approved manufacturing facilities across the globe, with two based in the U.S. West-Ward has grown at a rate faster than that of the consolidated company, increasing the importance of the U.S. market to Hikma. In 2014, West-Ward represented 51% of Hikma's group sales.West-Ward was established in 1946 as a generic orals manufacturing company. With over 60 years of experience, West-Ward has a longstanding presence in the U.S. oral solid generics market, with a focus on quality manufacturing and high service levels. West-Ward has a broad portfolio with 41 oral products in 103 dosage forms. Some of the products for the non-injectable product line include Doxycycline, Amoxicillin, and Prednisone.West-Ward became the second largest injectable supplier by volume in the U.S. after the acquisition of Baxter's Multi-Source Injectables (MSI) division in 2011. Continuing the growth of the injectables business, in 2014, Hikma/West-Ward announced the acquisition of certain assets of Bedford Laboratories (the generic sterile injectables division of Boehringer Ingelheim), thereby adding to its injectable product portfolio. In combination with the existing injectables portfolio and FDA manufacturing facilities in Portugal and Germany, these acquisitions solidified the portfolio and reinforced West-Ward as a full-service generics manufacturer. West-Ward's injectable product portfolio includes 65 products in 184 dosage forms and strengths, including controlled substances. Some of the injectable products include Fentanyl, Morphine, Phenylephrine, Glycopyrrolate and Argatroban.Spiro Gavaris (West-Ward vice president, sales and marketing) believes that on the heels of the Bedford transaction, West-Ward has optimized the potential of their combined product portfolio, building stronger customer relationships, and increasing new product launches and product acquisitions with the expanded operating capacity."Our expanded capacity and site transferring of products optimizes our outputs and increases production for flexible manufacturing," explains Gavaris.West-Ward is focused on continuous supply given the span of the global market shortages across the industry. With the acquisition of manufacturing facilities in Portugal, Jordan, Saudi Arabia, and Germany, Hikma/West-Ward has expanded its capacity to produce quality pharmaceuticals.For more information, visit www.west-ward.com.- See more at:

[broadwood] 03/9/2015 08:30

Barclays raised the stock’s target price from £20.50 to £27.60 owing the move to the “Roxane Revolution”. Analysts at the bank reckon Hikma’s deal to buy US specialty generics business Roxane from German drugmaker Boehringer Ingelheim will “transform its long-term growth profile”.


Simon Mather, of Barclays, said “Hikma has transformed its US exposure and long-term visibility through the $2.65bn acquisition of Roxane”. “It marks the second transaction between Hikma and Boehringer so begs the question what is next,” he added, highlighting the pharmaceutical company can still comfortably finance deals of up to $1bn in magnitude.


The acquisition will also bolster its product offerings, in particular in the respiratory sphere, and will allow it participate in lucrative first to file opportunities. Barclays was not alone in its praise of Hikma, Shore Capital also applauded the company’s management team for “the execution of its business model through timely and complementary acquisitions”.


Dr Brian White, of Shore Capital, noted “while we have been less enthusiastic regarding the outlook for the oral generics business, we concede that the recently announced acquisition of Roxane provides greater scale and sustainability”;. The positive stances from the brokers boosted the stock, closing

[broadwood] 02/9/2015 14:28

News) - Hikma Pharmaceuticals got a shot in the arm on Wednesday as Barclays lifted its price target on the stock to 2,760p from 2,050p.
The bank said Hikma has transformed its US exposure and long-term visibility through the $2.65bn acquisition of US specialty generics company Roxane.

"The closure of the deal transforms Hikma's presence in the US, its long-term growth trajectory, and the reliance on shortage drug opportunities," said Barclays.

"Boosting outer year earnings by over 20%, the deal revolutionises future opportunities, not only via portfolio-bolstering but also enabling lucrative paragraph IV and first-to-file opportunities."

Aside from the deal, it pointed to other significant sources of upside to its base-case assumptions, such as the accelerated transfer of Bedford products, the scope for cost savings and surprise product reintroductions.

Barclays said Jordan-based Hikma has a strong portfolio of branded products and with its high barriers to entry, the group is well positioned to benefit from the growing middle class.

Barclays rates the stock at 'overweight'

[discodave4] 02/9/2015 09:58

Only AHT, HIK on my watch list, waiting!.GLDD

[broadwood] 02/9/2015 09:49

Thanks DD. Hope you're in both aswell

[discodave4] 02/9/2015 09:18

Just happened to glance at it this morning and saw HIK.http://investing.thisismoney.co.uk/broker-views/Your having a good start to the day, with AHT and here. DD

[broadwood] 02/9/2015 08:51

DD - can I ask what site you use for Broker recs?

I subscribe to Broker Forecasts but no mention of the upgrade on there.

Thanks broadwood.

[discodave4] 02/9/2015 08:40

Barclays reiterates overweight, raises target to 2760.DD

[r ball] 02/9/2015 08:18

surprising.

[broadwood] 02/9/2015 08:13

Strong action so far. Broker upgrade?

[karateboy] 28/8/2015 00:20

Director buying may help share price to settle >£24.

[coppertrader] 21/8/2015 07:18

Hikma Pharmaceuticals, a world leader in the pharmaceuticals industry that is headquartered in London, has announced it wants to build a new pharmaceuticals plant in Almaty, Kazakhstan, Aynur Karimova writes for Azernews.Company representatives announced the plan during a session with Kazakh Investment and Development Minister, Aset Isekeshev at the Central Communications Service in the capital of Astana.The facility will correspond with international GMP standards, and construction is set to begin later this year. Project cost will be up to 11 billion tenge. Hikma says the facility will produce antibiotics and drugs to treat diabetes as well as central nervous disorder ailments.The plant's products will be sold on both the domestic and international markets. International target markets will include the Commonwealth of Independent States (CIS), Central Asia, and Eastern Europe.Read more at Azernews.

[r ball] 19/8/2015 23:21

Hardly. Relief rally. Underwhelmed

[scottishfield] 19/8/2015 07:52

Yes v good rns this morning imo

[broadwood] 19/8/2015 07:45

StockMarketWire.com - Hikma reports a solid H1 performance in line with expectations and is on track to achieve full year guidance. The group said revenues of $709 million were in line with H1 2014 in constant currency, but down 4% on a reported basis, with good performances from Branded and Injectables, offset by the expected decline in specific market opportunities in Generics. Full year group revenue guidance is maintained at around 6% growth in constant currency, or 2% on a reported basis. Group adjusted operating profits fell to $204 million, compared with $244 million in H1 2014 and basic EPS of 67.3 cents per share - 21% down on last time. The interim dividend of 11.0 cents per share is in line with total dividend paid in H1 2014. Chief executive Said Darwazah said: "We have had an excellent start to the year. Our financial results are in line with expectations and we are making strong strategic progress across the Group. "The acquisition of Roxane, agreed in July, will transform our business in the US, adding complementary and well differentiated products, an attractive pipeline, proven R&D capabilities and greater overall scale. It also provides an excellent opportunity to expand our product portfolio in other markets, particularly the MENA region. "Bedford is now well integrated, we have launched the first of their generic injectable products and we are confident that we will continue to bring a steady stream of these products back to the market. The addition of Bedford and Roxane to our US businesses will enable us to capture growth opportunities in more specialised segments of the US generics market. "Our businesses in MENA are performing very well and we are strongly positioned for continued growth. Our partnership with Vitabiotics, announced today, will leverage our marketing and sales capabilities in MENA and broaden our product portfolio, and is a great example of how we are implementing our growth strategy in the region. "We have taken important strategic steps this year and we are very excited about the opportunities these bring to the Group. Across our geographies, we have strong market positions, we are executing well and we are very confident in the outlook for 2015 and beyond." - See more at:

[r ball] 18/8/2015 21:49

Results tomorrow.

[r ball] 18/8/2015 20:15

growth trend too linear. will Iran rapprochement open up new markets or increase competition from us co. entry?

[coppertrader] 18/8/2015 18:56

The Jordanian drug maker Hikma Pharmaceuticals has an appetite for more acquisitions as it seeks to double its revenue every four years, a company executive said."We are looking for opportunities for acquisitions in this part of the world and other parts," said Mazen Darwazah, president and chief executive of Mena and emerging markets."Our leverage is still in a range where we can do more acquisitions, and we still have good scope to do other smaller acquisitions as we go forward."London-listed Hikma last month agreed to acquire the US generic drugs business of Boehringer Ingelheim for US$2.65 billion as it looks to bolster its US and generics market share.Last year, Hikma bought the assets of Bedford Laboratories, an Ohio-based maker of injectable drugs, for $300 million, also from Boehringer Ingelheim.The Amman-based company posted a 21 per cent rise in pretax profit to $362m last year, even as sales from its generics division plummeted. Overall revenue grew 9 per cent to $1.48bn.Nevertheless, the group, warned that its revenue growth forecast of 6 per cent for this year at constant exchange rates could be affected by about 3 per cent or $45m if current forex trends persist, such as the euro's weakness against the US dollar. But the firm still has big ambitions."We will develop and aspire to double in size every four years," said Mr Darwazah. Since 2005, the company's revenue has grown at a compound annual growth rate of 21 per cent as acquisitions helped to boost profitability.Hikma also is venturing into new territories and returning to markets where it once operated in, but left due to a lack of ­governance."We believe that now is a good time to go to China and Sub-Saharan Africa because of the need for health care and the establishment of strong governance controls," said Mr Darwazah.The company has also set sights on the Commonwealth of Independent States countries for growth. It has identified land for operations in Kazakhstan. Hikma started off in 1978 with the manufacturing of branded generic pharmaceutical products for the Middle East market. In the 1990s it started to expand outside Mena.In 2005, it listed on the London Stock Exchange, and started an aggressive acquisitions strategy, snapping up assets from US to Egypt.The US is increasingly contributing more of group revenues at 51 per cent last year, up from 46 per cent a year earlier. The Mena market contributed 43 per cent of revenues, down from 47 per cent in 2013.The injectable drugs business accounted for 48 per cent of total group revenues last year, up from 39 per cent, while the generics division accounted for 15 per cent of the revenues, down from 20 per cent. The rest was held by branded medicines."We are scanning opportunities in different asset classes in both orals, injectables, in oncology business, in the biosimilar [large molecule generics] business," said Mr Darwazah.Hikma has 27 manufacturing facilities in 11 countries, and its products are sold in over 50 countries worldwide."We are looking at opportunities for growth in the Mena region," said Mr Darwazah. "Governments are spending more, we have population growth and we have many therapeutic classes not covered in the Mena region."The Arabian Gulf healthcare market is projected to grow at an annual rate of 12 per cent to $69.4bn by 2018 from $39.4bn in 2013, according to Alpen Capital, a Dubai-based financial services advisory firm."We are witnessing a huge number of patients coming in with diabetes and obesity in the Mena region," said Mr ­[e-mail] The National's Business section on Twitter

[mike740] 03/8/2015 20:26

Not on me your not jabba.

Next youl be wanting me left right and centre.......bum boy.

[thejaba] 03/8/2015 15:07

even lower